Significance of serum antibodies reactive with flavoprotein subunit of succinate dehydrogenase in thyroid associated orbitopathy

British Journal of Ophthalmology

Volumn 83, Issue 5, 1999, Pages 605-608

  Hosal, Banu M ^a,b   Swanson, Jil K ^a   Thompson, Charlotte R ^a   Kubota, Sumihisa ^a   Gunji, Kazuaki ^a   Kennerdell, John S ^a   Wall, Jack R ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b Iran Caddesi 55/4   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FLAVOPROTEIN; PROPYLTHIOURACIL; SUCCINATE DEHYDROGENASE; THIAMAZOLE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBUNIT; EXTRAOCULAR MUSCLE; FEMALE; HUMAN; MALE; ORBIT; ORBIT DISEASE; PRIORITY JOURNAL; SMOKING; THYROID DISEASE;

EID: 0032903513     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.83.5.605     Document Type: Article

References (23)

1. Dresner SC, Kennerdell JS. Dysthyroid orbitopathy. Neurology 1985;35:1628-34.
2. Goldberg RA. Evaluation and spectrum of orbital diseases. In: Stewart WB, ed. Surgery of the eyelid, orbit, and lacrimal system. Ophthalmology monographs 8. San Francisco: American Academy of Ophthalmology, 1994;3:2-19 (chapter 25).
3. Gerding MN, Terwee CB, Dekker FW, et al. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 1997;7:885-9.
4. Tallstedt L, Lundell G, Torring Q, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;326:1733-8.
5. Kung AWC, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methirnazole. J Clin Endocrinol Metab 1994;79:542-6.
6. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8.
7. Nunery WR, Martin RT, Heinz GW, et al. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthalmic Plast Reconstr Surg 1993;9:77-82.
8. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993;269:479-82.
9. Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol 1994; 40:67-72.
10. Prummel MF, Wiersinga WM. Medical management of Graves' ophthalmopathy. Thyroid 1995;5:231-4.
11. Wiersinga WM, Irnmunosuppressive treatment of Graves' ophthalmopathy. Thyroid 1992;2:229-33.
12. Weetman AP, Extrathyroidal complications of Graves' disease. Q J Med 1993;86:473-7.
13. Weetman AP, Cohen S, Gatter KC, et al. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989;75:222-7.
14. Kiljanski JI, Nebes V, Wall JR. The ocular muscle cell is a target of the immune system in endocrine ophthalmopathy. Int Arch Allergy Immunol 1995;106:204-12.
15. Arnold K, Tandon N, Mcintosh RS, et al. T cell responses to orbital antigens in thyroid-associated ophthalmopathy. Clin Exp Immunol 1994;96:329-34.
16. Kubota S, Gunji K, Stolarski C, et al. Reevaluation of the prevalences of serum autoantibodies reactive with "64-kd eye muscle proteins" in patients with thyroid-associated ophthalmopathy. Thyroid 1998;8:175-9.
17. Kubota S, Gunji K, Ackrell BAC, et al. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1998;83:443-7.
18. Committees of the American, European, Japanese, Asia-Oceania and Latin-American Thyroid Associations. Classification of eye changes of Graves' disease. Thyroid 1992;2:235-6.
19. Kodama K, Sikorska H, Bandy-Dafoe P, et al. Demonstration of circulating autoantibody against a soluble eye muscle antigen in Graves' ophthalmopathy. Lancet 1982;2: 1353-6.
20. Chang TC, Chang TJ, Huang YS, et al. Identification of autoantigen recognized by autoimmune ophthalmopathy sera with immunoblotting correlated with orbital computed tomography. Clin Immunol Immunopath 1992;65:161-6.
21. Hiromatsu Y, Sato M, Tanaka K, et al. Significance of antieye muscle antibody in patients with thyroid-associated ophthalmopathy by quantitative western blot. Autoimmunity 1992;14:9-16.
22. Madaio MP, Yanase K, Foster MH, et al. Nuclear localization of autoantibodies. Novel insights into protein translocation and cellular function. Ann NY Acad Sci 1997; 815:263-6.
23. Kagoshima T, Hori S, Inoue Y. Qualitative and quantitative anaylses of Muller's muscle in dysthyroid ophthalmopathy. Jpn J Ophthalmol 1987;31:646-54.